UPDATE 2-Bristol won't seek faster Opdivo/Yervoy lung cancer approval
Jan 19 (Reuters) - Bristol-Myers Squibb Co on Thursday said it has decided not to seek accelerated U.S. approval for a combination of its two immunotherapy drugs as an initial treatment for lung... [Source]
Publication Date:Origin: reuters.com
Category: hotStocksNews
Topics: approval, treatment, an initial, drugs, immunotherapy, combination, accelerated, decided, on Thursday, Squibb, Bristol-Myers, (Reuters), cancer, Opdivo/Yervoy, faster, won't, 2-Bristol, UPDATE